Cytokinetics (CYTK) Earns Coverage Optimism Rating of -0.07

News coverage about Cytokinetics (NASDAQ:CYTK) has been trending somewhat negative this week, according to Accern Sentiment. The research firm identifies positive and negative press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Cytokinetics earned a media sentiment score of -0.07 on Accern’s scale. Accern also assigned media coverage about the biopharmaceutical company an impact score of 45.8495336961003 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

Here are some of the news headlines that may have effected Accern Sentiment’s rankings:

A number of equities analysts have issued reports on CYTK shares. HC Wainwright reiterated a “buy” rating and set a $20.00 price target on shares of Cytokinetics in a research note on Friday, April 27th. Cantor Fitzgerald reiterated a “hold” rating and set a $10.00 price target on shares of Cytokinetics in a research note on Sunday, June 17th. BidaskClub upgraded Cytokinetics from a “sell” rating to a “hold” rating in a research note on Saturday, April 28th. ValuEngine upgraded Cytokinetics from a “sell” rating to a “hold” rating in a research note on Friday, April 27th. Finally, Piper Jaffray Companies cut their price target on Cytokinetics to $13.00 and set an “overweight” rating for the company in a research note on Monday, June 18th. Four analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Cytokinetics presently has a consensus rating of “Buy” and an average target price of $15.56.

Cytokinetics traded down $0.30, reaching $8.35, during mid-day trading on Tuesday, Marketbeat.com reports. 251,280 shares of the company traded hands, compared to its average volume of 366,893. The company has a market capitalization of $455.26 million, a P/E ratio of -3.22 and a beta of 1.17. The company has a debt-to-equity ratio of 0.32, a quick ratio of 7.07 and a current ratio of 7.07. Cytokinetics has a fifty-two week low of $6.75 and a fifty-two week high of $15.95.

Cytokinetics (NASDAQ:CYTK) last announced its earnings results on Thursday, April 26th. The biopharmaceutical company reported ($0.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.06). Cytokinetics had a negative return on equity of 99.50% and a negative net margin of 172.27%. The business had revenue of $5.27 million during the quarter, compared to analysts’ expectations of $5.50 million. sell-side analysts forecast that Cytokinetics will post -1.99 earnings per share for the current fiscal year.

In other news, EVP Fady Ibraham Malik sold 3,000 shares of the business’s stock in a transaction that occurred on Thursday, June 7th. The stock was sold at an average price of $8.95, for a total value of $26,850.00. Following the transaction, the executive vice president now owns 96,067 shares in the company, valued at approximately $859,799.65. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Robert I. Blum sold 4,000 shares of the business’s stock in a transaction that occurred on Thursday, April 5th. The stock was sold at an average price of $7.52, for a total value of $30,080.00. Following the completion of the transaction, the chief executive officer now owns 182,701 shares in the company, valued at approximately $1,373,911.52. The disclosure for this sale can be found here. Insiders sold a total of 15,000 shares of company stock worth $123,570 in the last 90 days. Company insiders own 5.10% of the company’s stock.

Cytokinetics Company Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is developing small molecule drug candidates primarily engineered to increase muscle function and contractility.

Insider Buying and Selling by Quarter for Cytokinetics (NASDAQ:CYTK)

Receive News & Ratings for Cytokinetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply